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Abstract
Hidradenitis suppurativa (HS)/acne inversa is a debilitating chronic disease that remains poorly understood and difficult
to manage. Clinical practice is variable, and there is a need for international, evidence-based and easily applicable con-
sensus on HS management. We report here the findings of a systematic literature review, which were subsequently used
as a basis for the development of international consensus recommendations for the management of patients with HS. A
systematic literature review was performed for each of nine clinical questions in HS (defined by an expert steering com-
mittee), covering comorbidity assessment, therapy (medical, surgical and combinations) and response to treatment.
Included articles underwent data extraction and were graded according to the Oxford Centre for Evidence-based Medi-
cine criteria. Evidence-based recommendations were then drafted, refined and voted upon, using a modified Delphi pro-
cess. Overall, 5310 articles were screened, 171 articles were analysed, and 65 were used to derive recommendations.
These articles included six randomized controlled trials plus cohort studies and case series. The highest level of evi-
dence concerned dosing recommendations for topical clindamycin in mild disease (with systemic tetracyclines for more
frequent/widespread lesions) and biologic therapy (especially adalimumab) as second-line agents (following conven-
tional therapy failure). Good-quality evidence was available for the hidradenitis suppurativa clinical response (HiSCR) as
a dichotomous outcome measure in inflammatory areas under treatment. Lower-level evidence supported recommenda-
tions for topical triclosan and oral zinc in mild-to-moderate HS, systemic clindamycin and rifampicin in moderate HS and
intravenous ertapenem in selected patients with more severe disease. Intralesional or systemic steroids may also be
considered. Local surgical excision is suggested for mild-to-moderate HS, with wide excision for more extensive dis-
ease. Despite a paucity of good-quality data on management decisions in HS, this systematic review has enabled the
development of robust and easily applicable clinical recommendations for international physicians based on graded
evidence.
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Introduction
Hidradenitis suppurativa (HS)/acne inversa is a debilitating,
chronic, inflammatory skin disease that, for the most part,
remains poorly understood and managed. The prevalence of HS
is estimated to be around 1% of the general population, it occurs
more frequently in females than males, and it usually presents
after puberty.1 Keratin plugging of hair follicles and recurrent
inflammation lead to the formation of painful nodules and
abscesses that rupture, causing sinus tracts (tunnels) and scar-
ring.1,2 Patients often experience long delays before an HS diag-
nosis is established.2 Moreover, the disease is often associated
with a significant negative impact on quality of life.2
Hidradenitis suppurativa is difficult to treat, and clinical prac-
tice is variable; therefore, there remains a large unmet medical
need in this area. Evidence-based treatment guidelines for HS
are rare; the original S1 guidelines developed by the European
© 2018 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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Dermatology Forum,1 a revised version including graded levels
of evidence and first-, second- and third-line treatment recom-
mendations,2 and national guidance publications3–5 are some of
the few resources currently available. There is a need for interna-
tional, evidence-based consensus on management of HS that is
widely and easily applicable in clinical practice.
The aim of the HS ALLIANCE working group was to develop
international consensus recommendations for the treatment and
management of patients with HS, which go beyond the current
guidelines and provide practical suggestions on how tools and
treatments should be used. The recommendations cover key
areas identified by the International Steering Committee (ISC)
as imperative to address, including comorbid diseases, antibiotic
and biologic therapies, surgical interventions and monitoring.
Methods
HS ALLIANCE working group
The working group consists of an ISC of experts in the field of
dermatology and dermatologic surgery, bibliographic fellows
(nominated by the ISC) and national faculty members (known
physicians with an interest in HS; Appendix S1). Together, they
represent 25 countries worldwide.
The ISC identified a number of key areas for clinical focus in
HS and defined a list of clinical questions that should be
answered in order to develop consensus recommendations,
using a modified Delphi consensus process (Fig. 1). These
questions were ranked and refined by the national faculty, clini-
cal care gaps were identified, and a final list of nine overarching
questions was selected.
To address these questions, systematic literature searches were
performed by the bibliographic fellows, supported by the ISC
and a report containing draft evidence-based statements devel-
oped for review by the national faculty. Several hundred com-
ments were reviewed and incorporated by the ISC (assisted by
the bibliographic fellows), and a final consolidated report was
prepared for the working group. The report was then discussed
at a face-to-face meeting (Copenhagen, Denmark, on 10 and 11
February 2017), at which the group refined and voted upon the
draft recommendations.
Literature search
For each clinical question to be answered (nine in total), a bibli-
ographic fellow performed a systematic literature search. Search
terms and strings were constructed and tested in conjunction
with the ISC. Search strings incorporated both Medical Subject
Headings (MeSH) and free text key words (Appendix S1). Data-
bases searched include PubMed/Medline, The Cochrane Library,
EMBASE, CINAHL, SCOPUS, BIOSIS and Web of Science. Fur-
ther manual searches were conducted, as required, for recent
abstracts, trial registries and relevant articles from reference lists.
Included study designs comprised randomized controlled tri-
als (RCTs), prospective and retrospective studies, case series with
≥10 cases and other peer-reviewed articles. Animal studies, single
Figure 1 Representation of the modified Delphi process used to reach consensus.
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case studies or case series with <10 patients, narrative reviews,
editorials and non-peer-reviewed articles were excluded. Studies
considered had to be published between August 1996 and the
date of this review (August 2016), and be in English language.
Identified articles underwent a two-stage screening process:
firstly, titles and abstracts were scanned for relevance to the clini-
cal question being investigated, and secondly, full-text copies of
relevant articles were obtained and reviewed against the inclu-
sion and exclusion criteria, and any duplicate, low-quality or
outdated articles were excluded.
Included articles had the following data extracted: study char-
acteristics, including design, setting/data source and study per-
iod; participant characteristics, such as sample size, mean age,
sex, mean follow-up (if applicable) and location of the disease;
baseline (pretreatment) characteristics, where applicable; severity
of HS and treatment history to assess homogeneity within popu-
lations; treatment, where applicable, including type, dosage and
length of treatment; and outcomes after treatment, where appli-
cable (defined per question).
Evidence was rated by the bibliographic fellows working on
each clinical question (individuals or pairs), using the Oxford
Centre for Evidence-based Medicine criteria (http://www.cebm.
net/index.aspx?o=1025). Data extraction and reporting were
performed according to the 2009 PRISMA statement (http://
www.prisma-statement.org/PRISMAStatement/PRISMAStateme
nt.aspx) (Appendix S2).
Development of evidence-based statements
A report summarizing the collected evidence was prepared for
each question, including evidence ratings and draft evidence-
based statements; this was reviewed by the ISC before sending
out to the national faculty for review. Each participating nation
organized a local faculty meeting, at which the faculty indicated
their agreement with the draft statements, discussed any con-
cerns and suggested any wording amends. These discussions and
revisions were captured in a meeting report from each nation
and were passed to the ISC for review. The ISC considered all
national faculty feedback and prepared a consolidated report
with revised statements for each clinical question. The consoli-
dated report was sent to the working group for review ahead of
the international meeting, at which the ISC and national faculty
representatives voted on each evidence-based statement.
Voting process
Individuals assigned each statement an ‘agreement score’
between 1 (lowest) and 9 (highest), and these scores were col-
lated into one of three ranges: 1–3, 4–6 and 7–9. Level of agree-
ment was indicated by the percentage of individuals scoring
within the 7–9 range; if ≥75% of individuals scored a statement
within the 7–9 range, agreement was recorded. If no agreement
was achieved, the statements were discussed and amended with
agreement from the ISC co-chairs, and voting took place again.
If agreement was not achieved after a second vote, a lack of
agreement was recorded. One vote was allowed per country
among the national faculty members, and one vote for each
member of the ISC.
Results
In total, 5310 articles were screened and 171 were included in
the data analysis. Very few RCTs have been conducted in HS;
therefore, many of the available data were from case series or
expert opinion (grade 4 or 5 evidence).
Assessment of comorbidities
Fewer than 20 articles were available to guide practice around
assessment of comorbidities in patients with HS; nonetheless,
much of the available evidence was high grade (level 1 or 2).
Recommendations on assessment of comorbid disorders in
patients with HS are presented in Table 1 and summarized
below.
The association between HS and smoking is particularly
strong, although a causal relationship has not been ascertained.
An increased risk of metabolic syndrome in HS is recognized,6–9
with associated increases in risk for cardiovascular (CV) events
and mortality; notably, the risk of CV death is 58% higher in
patients with HS than in patients with severe psoriasis.10 Obesity
is also a well-established independent risk factor for HS,11–15
with improvements in disease severity demonstrated after weight
loss.12,16,17 Reflecting the psychological and physical burden of
the disease, rates of depression and anxiety among HS patients
are significantly increased compared with age- and gender-
matched controls.18
Other severe inflammatory conditions, such as Crohn’s dis-
ease and spondyloarthropathy, can co-exist in HS patients.19 In
addition, HS lesions can undergo malignant transformation into
squamous cell carcinoma. This is a rare occurrence, but is associ-
ated with a high mortality rate.20
Nonetheless, an association with comorbidity does not infer a
recommendation for widespread screening in HS; clinicians
should adhere to the latest population-based screening recom-
mendations in distinct populations, e.g. screening for metabolic
syndrome in obese patients.
Treatment
Medical therapy Apart from topical clindamycin and systemic
tetracycline, the evidence for efficacy of non-biologic agents in
HS comes from level 4 studies and expert opinion, including the
previous European S1 guidelines. The size and design of studies,
as well as the absence of long-term data for non-biologic treat-
ments, make standardized recommendations on optimal man-
agement challenging (Table 2).
The evidence-based literature available on the use of antibi-
otics in HS is limited and largely restricted to retrospective
© 2018 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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studies. The combination of systemic clindamycin and rifampi-
cin is by far the most investigated treatment. For Hurley stage I/
II, topical clindamycin 1% is a possible therapy, especially in the
absence of abscesses.22,23 If there are several lesions and frequent
exacerbations, the therapeutic group of systemic tetracyclines
may be considered.23 A triple regimen of rifampicin (10 mg/kg
once daily), moxifloxacin (400 mg once daily) and metronida-
zole (500 mg thrice daily) administered for up to 12 weeks, with
metronidazole discontinuation after 6 weeks, may be an alterna-
tive option. In Hurley stage II/III patients who have several
active lesions, systemic clindamycin and rifampicin (dosage:
300 mg twice daily) should be administered.24–27
Six RCTs assessing the use of biologic therapy have been per-
formed to date in HS (four of them with adalimumab), and two
more are ongoing. Recommendations for the use of these agents
are based on the results of these trials. Adalimumab should be
considered as the first-choice biologic agent in moderate/severe
HS after failure of conventional treatments,28–30 followed by
infliximab31 and anakinra32 as second- and third-line options,
respectively.
Evidence for combination therapies is very limited and largely
focused on small case series or retrospective reviews of antibi-
otics, topical triclosan and oral zinc or steroid-based therapies.
Surgical therapy The evidence for surgical therapies in HS is
based on case series and cohort studies with differing method-
ologies and outcome definitions (low-grade evidence; Table 3).
The type of surgery performed and the required margins are
based on the severity of the disease.1 For limited disease with
solitary lesions, individual abscesses may be drained as a supple-
mental measure,47–50 and surgical procedures, such as limited
excision, deroofing and STEEP, can be performed.51 For tense
and painful abscesses, no medical therapy will be effective and
surgical drainage may be required;52 however, this should not be
considered as sole treatment, because recurrence is almost inevi-
table. Widespread, severe disease requires more extensive exci-
sion.53–55 Chronic inactive lesions can be removed to prevent
recurrence.56,57
There is limited evidence for the combination of medical and
surgical therapies in HS. Studies in other immune-mediated
Table 1 Recommendations for assessment of comorbid disorders in patients with HS
What comorbidity-related screening should be assessed in patients with HS?
Comorbidities and risk factors for HS include (evidence level, grade of recommendation):
• Smoking (1, A)
• Cardiovascular disease (2, B)
• Metabolic syndrome (2, B)
• Obesity (2, B)
• Depression (3, B)
• Diabetes mellitus (3, B)
• Hypertension (3, B)
• Hypertriglyceridemia (3, B)
• Spondyloarthropathy (3, B)
• Crohn’s disease (4, C)
Treatment of HS should include careful assessment of comorbid disorders and risk
factors, referral for appropriate diagnosis and treatment when needed and
consideration of the impact of these factors on HS treatment decisions.
Pretreatment screening should be performed where necessary
Consensus (93%)
• 0% range 1–3
• 7% range 4–6
• 93% range 7–9
Weight loss/reduction in body mass index (obese patient; BMI ≥ 30) can be effective in reducing
severity of disease in the long term12,16 (evidence level 4, grade of recommendation C).
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
When assessing patients, particular emphasis should be paid to psychological comorbidity18
(evidence level 5, grade of recommendation D).
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
In patients with chronic perianal and perineal HS, and in particular in the presence of fistulas, the possibility
of Crohn’s disease should be considered21 (evidence level 5, grade of recommendation D).
Consensus (96%)
• 4% range 1–3
• 0% range 4–6
• 96% range 7–9
The potential for malignant transformation in patients with chronic HS should be recognized20
(evidence level 5, grade of recommendation D).
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
© 2018 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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Table 2 Recommendations for medical treatment of HS
Which non-biologic therapies are effective in the short, medium and long term for the treatment of HS?
There are very few long-term data26,33,34 Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
In Hurley stage II/III patients presenting with several active lesions, systemic clindamycin and rifampicin
(dosage: 300 mg twice daily) should be administered for an average length of 10 weeks24–27
(evidence level 4, grade of recommendation C).
Local antibiotic guidelines should be followed
The S1 European guidelines recommend that antibiotics should be used for up to 3 months and reintroduced
in case of recurrence under the requirement that they were effective at the last time of use1
(evidence level 5, grade of recommendation D)
Consensus (100%) [after revote]
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
Systemic acitretin may be considered as a third-line therapy for patients with mild/moderate HS35–38
(evidence level 4, grade of recommendation C).
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
Which antibiotics are and are not efficacious for the treatment of HS and how should they be used?
In Hurley stage I/II patients with mild localized HS with few lesions, topical clindamycin 1% is a possible
therapy, especially in the absence of deep inflammatory lesions (abscesses).23 The topical formulation
may be administered twice daily for a maximum of 3 months. Resistance to clindamycin has changed
since reviewed studies were completed; therefore, local antibiotic guidelines should be followed
(evidence level 2, grade of recommendation B).
Consensus (92%) [after revote]
• 0% range 1–3
• 8% range 4–6
• 92% range 7–9
In Hurley stage I/II patients presenting with several lesions and frequent exacerbations, the therapeutic
group of systemic tetracyclines may be considered23 (evidence level 2, grade of recommendation B).
However, many countries use other derivatives from the same group (e.g. doxycycline, minocycline),
for which there is no high-level evidence. Only one antibiotic of the same class should be used for
a maximum of 12 weeks. Local antibiotic guidelines should be followed.
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
In Hurley stage II/III patients presenting with several active lesions, systemic clindamycin
and rifampicin (dosage: 300 mg twice daily) should be administered for an average length of
10 weeks24–27 (evidence level 4, grade of recommendation C).
Local antibiotic guidelines should be followed.
Consensus (96%)
• 0% range 1–3
• 4% range 4–6
• 96% range 7–9
A triple regimen of rifampicin (10 mg/kg once daily), moxifloxacin (400 mg once daily) and
metronidazole (500 mg thrice daily) administered for up to 12 weeks, with metronidazole
discontinuation at week 6, may offer efficacy in Hurley stage I and II patients, but should be used
with appropriate monitoring39 (evidence level 4, grade of recommendation C).
Local antibiotic guidelines should be followed.
Consensus (81%)
• 0% range 1–3
• 19% range 4–6
• 81% range 7–9
In selected patients with severe HS, a 6-week course of intravenous ertapenem (1 g daily)
with consolidation treatment of rifampicin/moxifloxacin/metronidazole may be considered40
(evidence level 4, grade of recommendation C).
Local antibiotic guidelines should be followed.
Consensus (88%)
• 0% range 1–3
• 12% range 4–6
• 88% range 7–9
Antibiotics studied in HS (evidence level, grade of recommendation):
• Topical clindamycin 1% (2, B)
• Systemic tetracyclines (2, B)
• Combination therapy of systemic clindamycin and rifampicin (4, C)
• Triple regimen of rifampicin, moxifloxacin and metronidazole (single study) (4, C)
• Intravenous ertapenem (single study) (4, C)
• Systemic dapsone (single study)41 (4, C)
Consensus (96%)
• 0% range 1–3
• 4% range 4–6
• 96% range 7–9
There is no evidence for the use of other antibiotics Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
The S1 European guidelines recommend that antibiotics should be used for up to 3 months and
reintroduced in case of recurrence under the requirement that they were effective at the
last time of use1 (evidence level 5, grade of recommendation D).
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
In HS, microbiological cultures are not useful (evidence level 5, grade of recommendation D) Consensus (92%)
• 0% range 1–3
• 8% range 4–6
• 92% range 7–9
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diseases (psoriasis, psoriatic arthritis, rheumatoid arthritis and
inflammatory bowel disease) are insufficient to advise on preop-
erative interruption of biologics (Appendix S1).
Monitoring disease activity and response to therapy
Within the 13 RCTs performed in patients with HS, 90% of the
outcome measures lacked validated data to support their clinical
Table 2 Continued
How and when in the disease course of HS should biologics be introduced?
There are few RCTs and little high-quality evidence Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
Adalimumab should be considered as first-choice biologic agent in moderate/severe
HS after failure of conventional treatments28–30 (evidence level 2, grade of recommendation B).
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
Infliximab has also been shown to be effective and should be considered as a second-line
biologic for moderate/severe HS31 (evidence level 2, grade of recommendation B).
Consensus (81%)
• 4% range 1–3
• 15% range 4–6
• 81% range 7–9
Anakinra (evidence level 2, grade of recommendation B) has also been shown to
be effective and should be considered as a third-line biologic for moderate/severe HS32
Ustekinumab (evidence level 4, grade of recommendation C) is a potentially
effective treatment for moderate/severe HS42
Consensus (84%)
• 4% range 1–3
• 12% range 4–6
• 84% range 7–9
Etanercept is not effective for the treatment of HS43 (evidence level 2, grade of recommendation B). Consensus (96%)
• 0% range 1–3
• 4% range 4–6
• 96% range 7–9
When should (any) combinations of medical treatments be considered for
patients with HS and what combinations should be used?
Evidence for the use of combination therapy in HS is limited Consensus (92%)
• 0% range 1–3
• 8% range 4–6
• 92% range 7–9
In Hurley stage II/III patients presenting with several active lesions, systemic
clindamycin and rifampicin (dosage: 300 mg twice daily) should be administered for
an average length of 10 weeks24–27 (evidence level 4, grade of recommendation C).
Local antibiotic prescribing guidelines should be followed.
Consensus (100%) [after revote]
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
A triple regimen of rifampicin (10 mg/kg once daily), moxifloxacin (400 mg once daily)
and metronidazole (500 mg thrice daily) administered for up to 12 weeks, with
metronidazole discontinuation at week 6, may offer efficacy in Hurley stage I and II
patients, but should be used with appropriate monitoring39 (evidence level 4, grade of recommendation C).
Local antibiotic prescribing guidelines should be followed.
Consensus (100%) [after revote]
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
In Hurley stage I/II, the combination of oral zinc gluconate (30 mg thrice daily) and
topical triclosan 2% (twice daily) may be considered as a treatment option44
(evidence level 4, grade of recommendation C).
Consensus (81%)
• 0% range 1–3
• 19% range 4–6
• 81% range 7–9
Intralesional steroids may be helpful for acute inflammatory nodules in combination with
other treatments at all Hurley stages45 (evidence level 4, grade of recommendation C).
Consensus (80.8%)
• 11.5% range 1–3
• 7.7% range 4–6
• 80.8% range 7–9
Low-dose systemic corticosteroids (10 mg prednisolone equivalent per day) may be an
effective adjunct in recalcitrant HS46 (evidence level 4, grade of recommendation C).
Long-term corticosteroid treatment should be used with appropriate caution.
Consensus (96%)
• 0% range 1–3
• 4% range 4–6
• 96% range 7–9
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applicability. Seven studies of six different HS outcome measures
have provided validation data;11,14,63–67 however, one measure
[the acne inversa severity index (AISI)]64 is yet to be employed
in an RCT. Hurley stage measurements and Sartorius scoring are
widely used assessments of severity; however, these have limita-
tions and are only partially validated.14,63,67 Validated outcome
measures that may be used to assess changes in disease over time
or following treatment include the hidradenitis suppurativa clin-
ical response (HiSCR),66 which is supported by good-quality
evidence, and more general measures encompassing physician-
and patient-reported levels of extent, pain and quality of
life.11,64,65
High-level trial data for use of adalimumab in patients with
HS suggest that those patients who do not respond to treatment
Table 3 Recommendations for surgical treatment of HS
Which types of surgery may benefit patients with HS?
Case and cohort studies used variable definitions of recurrence and a wide range of follow-up time and,
therefore, cannot be compared.
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
In acute situations, surgical incision and drainage of tense and painful abscesses, i.e. fluctuant lesions, may be performed.
However, incision and drainage should not be considered as a sole treatment because recurrence is almost inevitable47–50
(evidence level 4, grade of recommendation C).
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
Surgical procedures, such as limited excision, deroofing and STEEP, can be used for solitary lesions of the disease.
They could be performed for recurrent HS lesions at fixed locations or fistula/sinus tract formation in limited areas51
(evidence level 4, grade of recommendation C).
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
Wide excision of the entire affected area, with removal of (non-)inflamed sinuses, nodules and scar tissue, may be performed
in Hurley stage III to prevent recurrence53–55 (evidence level 4, grade of recommendation C).
Consensus (96%)
• 0% range 1–3
• 4% range 4–6
• 96% range 7–9
Chronic HS lesions that have not shown any signs of inflammation for a prolonged period of time may be excised to prevent
further recurrence56,57 (evidence level 5, grade of recommendation D).
Consensus (78%)
• 7% range 1–3
• 15% range 4–6
• 78% range 7–9
Special attention should be paid to patients with perianal and/or perineal HS due to the possible existence of anal, urethral
and vaginal fistulas and presence of squamous cell carcinoma47,58 (evidence level 4, grade of recommendation C).
Consensus (92.6%)
• 3.7% range 1–3
• 3.7% range 4–6
• 92.6% range 7–9
CO2 ablative laser treatment is an effective alternative method to electrosurgical or cold steel techniques
59,60
(evidence level 4, grade of recommendation C).
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
How should medical and surgical treatments be integrated?
There are no RCTs describing the combination of medical and surgical treatments Consensus (92.6%)
• 3.7% range 1–3
• 3.7% range 4–6
• 92.6% range 7–9
Pre- and postoperative biologic therapy may lead to a lower recurrence rate and a longer disease-free interval61,62
(evidence level 4, grade of recommendation C).
Consensus (89%)
• 0% range 1–3
• 11% range 4–6
• 89% range 7–9
There is no current literature regarding adverse events when integrating biologic therapy and surgery in HS patients.
Studies in other immune-mediated diseases are insufficient to advise preoperative interruption of biologics
(evidence level 5, grade of recommendation D).
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
Adalimumab reduces the need for surgical procedures (incisions and drainage)29
(evidence level 2, grade of recommendation C).
Consensus (85.7%)
• 3.6% range 1–3
• 10.7% range 4–6
• 85.7% range 7–9
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(<25% improvement in abscesses and inflammatory nodules)
within 12 weeks should discontinue the drug, while partial or
good responders should continue the therapy with ongoing
assessment.28,29,68,69 Evidence is lacking for other biologic thera-
pies, and any clinical decisions should be based on close moni-
toring and risk : benefit assessments.
The working group recommendations for assessment of
disease and monitoring are given in Table 4.
Discussion
This systematic literature review demonstrates the paucity of an
evidence base for clinical decision-making in HS. This is both in
terms of the number of studies and the quality of the data
(Appendix S3). The highest level evidence available addresses the
use of topical and systemic antibiotics and biologic therapies,
especially adalimumab. The majority of the remaining evidence
to guide management decisions is based on case reports, small
cohort studies and expert opinion. The dearth of high-quality
evidence in HS strengthens the need for practical expert consen-
sus recommendations to optimize management worldwide and
improve care for these patients. The HS ALLIANCE of interna-
tional experts has reviewed the available data and has developed
these consensus clinical recommendations that are both prag-
matic and evidence-based.
Only 13 RCTs have been performed in HS; of these, seven
have not formed the basis of treatment recommendations made
Table 4 Recommendations for assessment of disease and monitoring
How should disease activity and response to treatment be monitored in patients with HS?
The majority of the outcome measurement instruments used in HS RCTs lack
substantial validation evidence. Furthermore, a validated measure for baseline
severity assessment is also unexplored. This may hamper comparisons of
HS trials investigating future treatment regimens
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
Hurley staging is suggested by experts for assessment of baseline severity,
especially with regard to the extent of scarring. It is, however, not a dynamic
tool and so it should only be used to describe an area affected by HS (and not to
define overall severity of disease). Each individual area affected by HS should be
assessed independently (evidence level 5, grade of recommendation D).
Consensus (96%)
• 0% range 1–3
• 4% range 4–6
• 96% range 7–9
The HiSCR is supported by good-quality validation studies and is recommended
to be used as a dichotomous outcome measure in inflammatory areas under treatment66
(evidence level 2, grade of recommendation B).
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
Patient-reported outcome measures (e.g. DLQI, VAS) should be included in the
overall assessment of the HS patient as they may offer important insight on functioning,
quality of life and symptoms (e.g. pain and itching)63,64 (evidence level 4, grade of recommendation C).
Consensus (100%)
• 0% range 1–3
• 0% range 4–6
• 100% range 7–9
The modified Sartorius score has been partially validated and can be used to
assess severity14,67 (evidence level 4, grade of recommendation C).
Consensus (96%)
• 0% range 1–3
• 4% range 4–6
• 96% range 7–9
How long should biologics be used in patients responding/not responding?
Adalimumab28,29,68,69:
 In patients with <25% improvement in abscess and inflammatory
nodule [AN] count after 12 weeks, treatment with adalimumab
should not be continued (evidence level 2, grade of recommendation B).
 For patients who do not achieve HiSCR, but achieve a 25–50%
improvement in AN count (partial response) after 12 weeks, consider
continuing treatment and re-evaluate after an additional 3 months
(evidence level 2, grade of recommendation B).
 In the short term, studies show recurrence following discontinuation
of treatment after 11–12 weeks (evidence level 4, grade of recommendation C).
 Long-term (at least 1 year) continuous treatment maintains a level
of consistent effectiveness in patient responders (evidence level 2, grade of recommendation B).
Consensus (92.6%)
• 3.7% range 1–3
• 3.7% range 4–6
• 92.6% range 7–9
Not enough published data are available for other biologics. Decisions about whether and
how to continue treatment should be based on a close monitoring of patients and
careful assessment of the risk : benefit ratio (evidence level 5, grade of recommendation D).
Consensus (96%)
• 0% range 1–3
• 4% range 4–6
• 96% range 7–9
DLQI, dermatology life quality index; VAS, visual analogue scale.
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in this review. This is due to the inclusion criteria of the review,
and limited clinical applicability or patient numbers (see
Appendix S1 for details).
Intense pulsed light and photodynamic therapy studies pro-
vide limited data for the treatment of HS. Their applicability to
widespread practice and outcomes is currently unknown. Fur-
ther research is warranted for these promising supplemental
therapies.
Topical clindamycin may be used in early HS; however, real-
world resistance to clindamycin tends to be higher than sug-
gested in a RCT, and the efficacy of topical clindamycin Hurley
stage II is questioned by many physicians. Systemic tetracyclines
are an alternative option, but these are no longer available in
some countries. The combination of 100 mg minocycline
administered orally once per day and 0.5 mg colchicine admin-
istered twice per day for 6 months, followed by maintenance
0.5 mg colchicine for 3 months, has recently been shown to pro-
vide substantial improvement or remission in a prospective pilot
study in 20 patients;70 further investigation of this combination
is warranted. For Hurley stage II/III HS, the use of systemic
antibiotic combinations is common, despite there being only
low-grade (level 4) evidence to support this. Furthermore, the
US Food and Drug Administration has recommended that fluo-
roquinolone antibiotics be reserved for patients with acute infec-
tions who have no alternative treatment options, due to a poor
risk : benefit profile (https://www.fda.gov/Drugs/DrugSafety/
ucm500143.htm). Long-term use of any antibiotic is not recom-
mended.
The use of intravenous ertapenem is included in this review as
a treatment option in selected severe patients, but its use is at
the discretion of the treating physician; the study on which this
recommendation is based included patients who were not surgi-
cal candidates, or who had been refused a surgical interven-
tion.40 This study was given the same grading as the evidence for
systemic clindamycin and rifampicin;24–27 however, the working
group considered the recommendation for ertapenem to be less
strong.
Adalimumab is considered the first-line biologic therapy in
HS due to the amount of high-level evidence available to
support its use. The indicated dose of adalimumab in HS is
160 mg on day 1, 80 mg on day 15 and a single 40 mg injection
every week from week 4 onwards. This is a higher dosing sched-
ule than that for plaque psoriasis, in which the recommended
regimen is 80 mg on day 1, 40 mg on day 8 and 40 mg every
other week thereafter. Infliximab also has high-level evidence to
support its use; nonetheless, the primary outcome of the RCT
investigating infliximab was neither validated nor achieved. The
dosing schedule for infliximab is 5 mg/kg body weight on day 0,
2 and 6 and then every 8 weeks. Anakinra was considered by the
group as third-line, despite having the same grade of evidence as
infliximab; this was due to the study including fewer patients
and different outcomes. Also, earlier studies of anakinra had
been less convincing than those for infliximab. Case reports of
etanercept suggest efficacy in HS; however, the performed RCT
showed no effect, and our recommendation is based on this
high-level evidence. Secukinumab was not included in these
recommendations due to lack of evidence at the time of the liter-
ature search; however, a pilot study for this drug in HS is now
underway (ClinicalTrials.gov Identifier: NCT03099980).
Many physicians managing HS routinely collect blood and
skin samples to assess bacterial cultures and treat their patients
according to the results. Traditional microbiological sampling is
not useful in HS and should not influence treatment decisions,
as there is no evidence for infection as a causal factor. Antibiotics
are prescribed in HS for their anti-inflammatory properties,
rather than for their antibacterial action; this may be an essential
point for physicians in their understanding of the pathogenesis
of HS. Likewise, antiseptics are commonly prescribed with no
evidence base to support their use, except for reducing smell.
The modified Sartorius score (MSS) has been partially vali-
dated as a tool to assess disease severity; however, it can be con-
sidered time-consuming to use, and several versions of this score
have been developed with inconsistent use of terminology, lead-
ing to confusion among physicians. For example, modified HS
score (modified HSS), MSS and HS-LASI (HS lesion, area and
severity index) are all used.14,29,71,72 The HiSCR has more valida-
tion data than other traditional severity tools; however, a further
validated tool to assess cross-sectional severity in HS has recently
been developed.73
The HS ALLIANCE working group highlighted a number of
future research topics for HS during consensus discussions.
Foremost, the group felt that new RCTs investigating individual
or combination therapies for HS were needed and that these
should include appropriate and validated outcome measures,
patient-reported outcomes and long-term data. The effect of
treatments for HS on associated CV risk factors was also an area
of potential interest, especially considering that use of met-
formin and anti-TNF-alpha agents in other diseases has been
associated with reduced CV risk.74,75 Evidence to guide optimal
practice for integrating medical and surgical therapies is also
required, along with further validation of outcome measures to
assess changes in HS activity over time and with treatment
response.
The paucity of high-level evidence on which to base clinical
recommendations, especially regarding optimal treatment strate-
gies for long-term and CV outcomes, was a limitation to this
systematic review. Furthermore, multiple literature reviewers
were involved, meaning that despite the same objectives and cri-
teria, slight differences occurred in the way the search strings
were designed and the data reviews were executed. Due to the
design of the consensus process, the literature searches were per-
formed in advance of the recommendations being finalized and
this review being written; therefore, some of the latest evidence,
including preliminary studies of spironolactone, ustekinumab
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and apremilast, was not considered within the recommenda-
tions. We would recommend that an update to these recommen-
dations and evidence grades is performed once ongoing RCTs
have reported, including any additional data that were not cap-
tured here.
The HS ALLIANCE recommendations in this review largely
agree with the current clinical practice guidelines in Europe,1,2
suggesting similar approaches for first- and second-line medi-
cal and surgical treatment options (Appendix S1; comparison
of current recommendations). The German guidelines and the
recent Swiss and Canadian guidance3–5 incorporated existing
evidence and practitioners’ expertise into a framework for the
evaluation and treatment of patients with HS, in a non-sys-
tematic fashion. Nonetheless, the discussed medical and surgi-
cal therapies align with those in the European S1 guidance,
albeit with a greater focus on hormonal and laser therapies in
Canada. The original European S1 guideline1 and the German
and Swiss guideline offered no methodology for creation of
the recommendations, but declared funding and conflict of
interests from the guideline groups. Building on these, Gul-
liver et al.2 reviewed and graded the available evidence behind
the therapeutic recommendations and created an algorithm
for management of HS, while providing more transparent
methodology and less conflict information. The current guide-
lines employed both a systematic, consensus approach and a
high level of transparency to generate recommendations that
address previously unanswered questions in clinical practice
and are clear to implement. A summary of the guideline rat-
ings is available in the Appendix S1.
In conclusion, there is currently a paucity of research evidence
available for HS, in terms of numbers of studies and quality of
data. Nonetheless, this systematic literature review captures and
grades the available evidence in order to provide applicable rec-
ommendations on important clinical questions for healthcare
professionals managing HS. The current international guidance
goes beyond the regional recommendations available, providing
a comprehensive and transparent set of consensus guidelines for
HS.
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